PDF(Pubmed)
Abstract：
UNASSIGNED: Gastrointestinal bleeding (GI) is a prevalent condition among pediatric patients, with a reported incidence of 6.4%, often severe enough to require admission to the pediatric intensive care unit (PICU). There are multiple therapies utilized in the management of GI bleeding in pediatrics, among which continuous intravenous (IV) infusion of omeprazole is used off-label without standard pediatric dosing recommendations. Reviewing the current literature reveals a lack of studies assessing the efficacy, safety, and appropriate dosing regimen of continuous omeprazole infusion in children with GI bleeding. This study aimed to evaluate the efficacy and safety of continuous IV omeprazole infusion in comparison to other therapeutic modalities in children.
UNASSIGNED: This study is a single-center, retrospective chart review of children admitted to the PICU at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. The treatment group included pediatric patients with GI bleeding and receiving omeprazole IV continuous infusion over ≥24 h while the control group included pediatric patients with GI bleeding managed using other therapies. Primary outcomes were the efficacy of omeprazole continuous infusion in stopping GI bleeding, and PICU length of stay (LOS). Secondary outcomes included instances of rebleeding post- therapy discontinuation, transfusion requirements, and the safety of omeprazole continuous infusion.
UNASSIGNED: The study included 81 critically ill pediatric patients, 22 of whom received continuous infusion omeprazole while 59 received other therapies. The results indicated that patients in the control group had a significantly shorter PICU LOS (8 vs. 18.5 days, p < 0.001) and bleeding episode (4 vs. 10.5 days, p < 0.001) than those in the treatment group. However, no significant differences were observed between the two groups regarding secondary outcomes. The treatment group had a significantly lower all-cause mortality rate during hospitalization compared to the control group (16 patients [72.7%] vs. 56 patients [94.9%], respectively, p = 0.005).
UNASSIGNED: Empirical use of omeprazole continuous intravenous infusion in children with GI bleeding was not favorable in terms of shortening PICU LOS and duration of GI bleeding. Our study results provide evidence supporting the safety and tolerability of omeprazole continuous infusion. Additional larger studies are necessary to determine the implication of such results.
UNASSIGNED: This study is a single-center, retrospective chart review of children admitted to the PICU at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. The treatment group included pediatric patients with GI bleeding and receiving omeprazole IV continuous infusion over ≥24 h while the control group included pediatric patients with GI bleeding managed using other therapies. Primary outcomes were the efficacy of omeprazole continuous infusion in stopping GI bleeding, and PICU length of stay (LOS). Secondary outcomes included instances of rebleeding post- therapy discontinuation, transfusion requirements, and the safety of omeprazole continuous infusion.
UNASSIGNED: The study included 81 critically ill pediatric patients, 22 of whom received continuous infusion omeprazole while 59 received other therapies. The results indicated that patients in the control group had a significantly shorter PICU LOS (8 vs. 18.5 days, p < 0.001) and bleeding episode (4 vs. 10.5 days, p < 0.001) than those in the treatment group. However, no significant differences were observed between the two groups regarding secondary outcomes. The treatment group had a significantly lower all-cause mortality rate during hospitalization compared to the control group (16 patients [72.7%] vs. 56 patients [94.9%], respectively, p = 0.005).
UNASSIGNED: Empirical use of omeprazole continuous intravenous infusion in children with GI bleeding was not favorable in terms of shortening PICU LOS and duration of GI bleeding. Our study results provide evidence supporting the safety and tolerability of omeprazole continuous infusion. Additional larger studies are necessary to determine the implication of such results.
摘要：
■胃肠道出血（GI）是儿科患者中普遍存在的疾病，报告的发病率为6.4%，通常严重到需要进入儿科重症监护病房（PICU）。有多种疗法用于儿科消化道出血的管理，其中奥美拉唑的连续静脉(IV)输注是在没有标准儿科给药建议的情况下使用的。回顾目前的文献发现，缺乏评估疗效的研究，安全,以及持续输注奥美拉唑治疗胃肠道出血患儿的适当给药方案。这项研究旨在评估儿童连续静脉输注奥美拉唑与其他治疗方式的疗效和安全性。
■这项研究是一个单中心，费萨尔国王专科医院和研究中心收治的PICU儿童的回顾性图表回顾，利雅得,沙特阿拉伯。治疗组包括胃肠道出血的儿科患者，并在24小时内接受奥美拉唑IV持续输注，而对照组包括使用其他疗法管理的胃肠道出血的儿科患者。主要结果是奥美拉唑持续输注在停止胃肠道出血中的疗效。和PICU住院时间（LOS）。次要结果包括治疗停止后再出血的情况，输血要求，和奥美拉唑持续输注的安全性。
■该研究包括81名危重儿科患者，其中22人接受持续输注奥美拉唑，59人接受其他治疗。结果表明，对照组患者的PICULOS明显较短(8vs.18.5天,p<0.001）和出血发作（4vs.10.5天,p<0.001）比治疗组。然而,两组间次要结局无显著差异.与对照组相比，治疗组住院期间的全因死亡率显着降低（16例患者[72.7％]vs.56例患者[94.9%]，分别,p=0.005)。
■在胃肠道出血患儿中使用奥美拉唑连续静脉输注在缩短PICU住院时间和胃肠道出血持续时间方面并不有利。我们的研究结果提供了支持奥美拉唑持续输注安全性和耐受性的证据。需要更多更大规模的研究来确定这些结果的含义。
■这项研究是一个单中心，费萨尔国王专科医院和研究中心收治的PICU儿童的回顾性图表回顾，利雅得,沙特阿拉伯。治疗组包括胃肠道出血的儿科患者，并在24小时内接受奥美拉唑IV持续输注，而对照组包括使用其他疗法管理的胃肠道出血的儿科患者。主要结果是奥美拉唑持续输注在停止胃肠道出血中的疗效。和PICU住院时间（LOS）。次要结果包括治疗停止后再出血的情况，输血要求，和奥美拉唑持续输注的安全性。
■该研究包括81名危重儿科患者，其中22人接受持续输注奥美拉唑，59人接受其他治疗。结果表明，对照组患者的PICULOS明显较短(8vs.18.5天,p<0.001）和出血发作（4vs.10.5天,p<0.001）比治疗组。然而,两组间次要结局无显著差异.与对照组相比，治疗组住院期间的全因死亡率显着降低（16例患者[72.7％]vs.56例患者[94.9%]，分别,p=0.005)。
■在胃肠道出血患儿中使用奥美拉唑连续静脉输注在缩短PICU住院时间和胃肠道出血持续时间方面并不有利。我们的研究结果提供了支持奥美拉唑持续输注安全性和耐受性的证据。需要更多更大规模的研究来确定这些结果的含义。
